Regulation of antioxidants in cancer.

NRF2 ROS antioxidants cancer glutathione oxidative stress

Journal

Molecular cell
ISSN: 1097-4164
Titre abrégé: Mol Cell
Pays: United States
ID NLM: 9802571

Informations de publication

Date de publication:
18 Nov 2023
Historique:
received: 18 08 2023
revised: 19 10 2023
accepted: 01 11 2023
medline: 30 11 2023
pubmed: 30 11 2023
entrez: 29 11 2023
Statut: aheadofprint

Résumé

Scientists in this field often joke, "If you don't have a mechanism, say it's ROS." Seemingly connected to every biological process ever described, reactive oxygen species (ROS) have numerous pleiotropic roles in physiology and disease. In some contexts, ROS act as secondary messengers, controlling a variety of signaling cascades. In other scenarios, they initiate damage to macromolecules. Finally, in their worst form, ROS are deadly to cells and surrounding tissues. A set of molecules with detoxifying abilities, termed antioxidants, is the direct counterpart to ROS. Notably, antioxidants exist in the public domain, touted as a "cure-all" for diseases. Research has disproved many of these claims and, in some cases, shown the opposite. Of all the diseases, cancer stands out in its paradoxical relationship with antioxidants. Although the field has made numerous strides in understanding the roles of antioxidants in cancer, many questions remain.

Identifiants

pubmed: 38029751
pii: S1097-2765(23)00917-6
doi: 10.1016/j.molcel.2023.11.001
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests I.S.H. reports financial support from Kojin Therapeutics and consulting fees for Ono Pharma USA. Funding and fees from these companies are outside the scope of the current work.

Auteurs

Fabio Hecht (F)

Department of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY 14642, USA; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14642, USA.

Marco Zocchi (M)

Department of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY 14642, USA; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14642, USA.

Fatemeh Alimohammadi (F)

Department of Pharmacology and Physiology, University of Rochester, Rochester, NY 14642, USA; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14642, USA.

Isaac S Harris (IS)

Department of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY 14642, USA; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14642, USA. Electronic address: isaac_harris@urmc.rochester.edu.

Classifications MeSH